© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
January 23, 2018
Tanios Bekaii-Saab, MD, FACP, Mayo Clinic Cancer Center, talks about key takeaways from the phase 2 ReDOS clinical trial for specialty pharmacists.
Kohei Shitara, MD, Department of Gastrointestinal Oncology of National Cancer Center Hospital East, Japan, discusses the importance of the REVERCE clinical trial for specialty pharmacists.
January 22, 2018
Prior treatment with sorafenib followed by pembrolizumab (Keytruda) shows promising progression-free survival and overall survival in patients with advanced hepatocellular carcinoma.
Cetuximab (Erbitux) with pembrolizumab (Keytruda) shows promise in patients with mCRC.
Induction therapy shows the potential to achieve disease control in patients with locally advanced pancreatic cancer.
A novel CTC assay showed up to 88% accuracy detecting precancerous and cancerous colorectal lesions.
Nivolumab (Opdivo) alone and in combination with ipilimumab (Yervoy) induced responses in patients with heavily pretreated gastrointestinal stromal tumors.
The addition of ramucirumab did not improve overall survival in patients with HER2-negative gastric cancer.
January 19, 2018
A combination VEGFR-2 inhibitor plus an antiâ€“PD-L1 agent demonstrated antitumor activity in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.
Cabometyx found to improve median overall survival by 2.2 months in patients with previously treated advanced hepatocellular carcinoma.